



ICTR-PHE 2012

<http://cern.ch/ICTR-PHE12>

International Conference
on Translational Research
in Radiation Oncology

Physics for
Health in Europe

Final Announcement and Call For Abstracts



February 27 – March 2, 2012
Centre International de Conférences de Genève (CICG)
International Conference Centre
Geneva, Switzerland

Organised in Collaboration with

ESTRO | EANM | ENLIGHT | ENTERVISION
ENVISION | ESO | ESRF | ILL | PARTNER | ULICE



PHYSICS for HEALTH
in EUROPE



Important dates:

Abstract submission and early registration deadline
Late registration

October 3, 2011
January 15, 2012



ICTR-PHE 2012



First ICTR-PHE 2012 Conference: Uniting Biology, Medicine and Physics for better healthcare

Dear Colleague,

On behalf of the Organizing Committee it is our privilege to invite you to attend ICTR-PHE 2012 (International Conference on Translational Research in Radio-Oncology and Physics for Health in Europe), which will take place in Geneva on February 27 – March 2, 2012.

This conference represents a new reality in Oncology, as it brings together two major events in the interdisciplinary field at the intersection of Medicine, Biology and Physics: the ICTR conference and CERN's Physics for Health workshop.

The ICTR conferences started in 2000 with the objective to update the radiation oncology community on the most recent advances in translational research, reinforce the synergies among clinicians, biologists and medical physicists, and, last but not least, trigger personal and institutional contacts favouring a more efficient collaboration between laboratories worldwide.

The first edition of the Physics for Health workshop was organised by CERN in February 2010 with the objective of reviewing the progress in the domain of physics applications in life sciences, stimulating the exchange between different teams and indicating the subjects most suitable for further studies in diagnosis and therapy. The workshop, which was the first of its kind, brought together some 400 healthcare professionals, biologists and physicists to examine the increasingly important interface between physics and health.

One of the main reasons to merge ICTR and PHE is to develop new strategies to treat cancer, by uniting biology and physics with clinics. These novel synergies will be the "red thread" that ICTR-PHE 2012 will follow during the whole conference.

The first two days (Monday, Tuesday) will be articulated into the four major topics defined during the previous Physics for Health workshop: radiobiology; radioisotopes; medical imaging; and novel technologies in radiation therapy. Wednesday will connect the PHE and ICTR communities, and will feature plenary lectures on the many synergies that exist nowadays between biology, physics and clinics. Finally, the last two days (Thursday, Friday) will have the format that made the success of the previous editions of the ICTR Conference, with a combination of plenary and parallel sessions on translational research and pre-clinical strategies in radiation oncology.

Importantly enough, this Conference will also develop further expansion of our partnership with industry, with concerted efforts in Research & Development and a common approach to emerging educational modalities in translational research. All this will be formalised through the publication of the Conference abstracts in a Supplement of "Radiotherapy and Oncology" fully dedicated to ICTR-PHE 2012.

Setting the stage for a new international conference is always a challenge, requiring an optimal coordination between all the components of the enterprise. But we are strongly convinced that the efforts we will put forth for a better integration along tracks where radiation physics, biology and medicine intertwine, will be key to success.

The Organizing Committee of ICTR-PHE 2012 is looking forward to welcoming you to Geneva so book February 27 – March 2, 2012 in your agenda now!



Jacques Bernier and Manjit Dosanjh,
Conference Chairs

Kian K. Ang, Ugo Amaldi, Michael Baumann,
Soeren M. Bentzen, Jacques Bernier,
Sergio Bertolucci, Jean Bourhis, Jean-François
Chatal, Alberto Del Guerra, Manjit Dosanjh,
Marco Durante, Wolfgang Enghardt, Zvi Fuks,
Ulli Köster, W. Gillies McKenna, R. Mohan,
Steve Myers, Ken Peach, and Brad Wouters,

Advisory Board



ICTR-PHE 2012



ICTR-PHE 2012 Scientific Committee

Advisory Board

Kian K. Ang (Pre-Clinical Strategies)
Ugo Amaldi (New Technologies)
Michael Baumann (Pre-Clinical Strategies)
Soeren M. Bentzen (Radiotherapy)
Jacques Bernier
Sergio Bertolucci
Jean Bourhis (Clinical Perspectives)
Jean-François Chatal (Nuclear Medicine)
Alberto Del Guerra (Detectors and Imaging)
Manjit Dosanjh
Marco Durante (Biology)
Wolfgang Enghardt (Detectors and Imaging)
Zvi Fuks (Clinical Perspectives)
Ulli Köster (Nuclear Medicine)
W. Gillies McKenna (Biology)
Radhe Mohan (Radiotherapy)
Steve Myers
Ken Peach (New Technologies)
Brad Wouters

Sections:

Biology

M. Durante, Darmstadt
W. G. Mc Kenna, Oxford
J.M. Brown, Stanford
B. Jones, Oxford
B. Wouters, Toronto

New Technologies

U. Amaldi, Novara
K. Peach, Oxford
S. Rossi, Milano
T. Haberer, Heidelberg

Pre-Clinical Strategies

K.K. Ang, Houston
M. Baumann, Dresden
M. Verheij, Amsterdam

Radiotherapy

S.M. Bentzen, Madison
R. Mohan, Houston
D.R. Olsen, Bergen
S. Korreman, Copenhagen

Nuclear Medicine

J.F. Chatal, Nantes
U. Köster, Grenoble
D. Lewis, CERN

Clinical Perspectives

J. Bourhis, Villejuif
Z. Fuks, New-York
J. Bernier, Genolier and Geneva
D. Brizel, Durham

Detectors and Imaging

W. Enghardt, Dresden
A. Del Guerra, Pisa
S. Bertolucci, CERN
P. Lecoq, CERN
D. Townsend, Singapore



ICTR-PHE 2012



ICTR-PHE 2012 Local Organizing Committee

D. Aebersold, Bern
S. Bodis, Aarau
G. Bolard, Genolier
S. Bulling, Geneva
T. Collen, Luzern
L. Cozzi, Bellinzona
N. Hejira, Genolier
J.C. Horiot, Genolier
T. Lomax, Villigen
R. Mirimanoff, Lausanne
M. Ozsahin, Lausanne
B. Pastoors, Geneva
M. Pruschy, Zürich
C. Vrieling, Geneva
D. Weber, Geneva
A. Ballantine, CERN
C. Brandt, CERN
M. Cirilli, CERN
H. Dixon-Altaber, CERN

ICTR-PHE 2012 Executive Committee

J. Bernier, Genolier and Geneva
S. Bertolucci, CERN
A. Costa, Milano
M. Dosanjh, CERN
R. Miralbell, Geneva
S. Myers, CERN

ICTR-PHE 2012 Faculty (as of June 2011)

U. Amaldi, TERA	E. Deutsch, Villejuif	M. Koritzinsky, Toronto	T. Robson, Belfast
K.K. Ang, Houston	M. Dewhirst, Durham	S. Korreman, Copenhagen	P. Rodemann, Tübingen
G. Barnett, Cambridge	E. Dikomey, Hamburg	U. Köster, Grenoble	S. Rossi, Milano
M. Baumann, Dresden	C. Dive, Manchester	M. Krause, Dresden	C. Ruegg, Lausanne
S.M. Bentzen, Madison	W. Doerr, Dresden	P. Lambin, Maastricht	K. Schilstra, Groningen
J. Bernier, Geneva	M. Dosanjh, CERN	G. Mageras, New-York	D.W. Siemann, Gainesville
S. Bertolucci, CERN	M. Durante, Darmstadt	E. Malinen, Oslo	J.J. Sonke, Amsterdam
T. Bortfeld, Boston	W. Enghardt, Dresden	M. Martin, Evry	F.A. Stewart, Amsterdam
J. Bourhis, Villejuif	J.T. Erler, London	W.G. McKenna, Oxford	I. Stratford, Manchester
A. Brahme, Stockholm	A. Fairchild, Brussels	R. Meyn, Houston	D. Townsend, Singapore
R. Bristow, Toronto	Z. Fuks, New-York	R. Miralbell, Geneva	S.L. Tucker, Houston
D. Brizel, Durham	J.P. Gérard, Nice	R. Mohan, Houston	V. Vandecasteele, Leuven
J.M. Brown, Stanford	A. Giaccia, Stanford	E. Moyal-Cohen, Toulouse	M. van Herk, Amsterdam
A.J. Chalmers, Glasgow	C. Grau, Aarhus	R.J. Muschel, Oxford	C. Vens, Amsterdam
E. Cohen-Jonathan Moyal, Toulouse	V. Grégoire, Brussels	S. Myers, CERN	M. Verheij, Amsterdam
C.N. Coleman, Washington DC	T. Haberer, Heidelberg	M. Nordmark, Aarhus	I. Vogelius, Copenhagen
R. Coppes, Groningen	M. Hauer-Jensen, Little Rock	D.R. Olsen, Bergen	M.C. Vozenin, Villejuif
N. Cordes, Dresden	E. Hammond, Oxford	R. Orecchia, Milano	D. Weber, Geneva
A. Costa, Milano	K. Harrington, London	J. Overgaard, Aarhus	B. Wouters, Toronto
J.D. Cox, Houston	K. Haustermans, Leuven	K. Peach, Oxford	D. Zips, Dresden
L. Dawson, Toronto	D.A. Jaffray,	J. Pouyssegur, Nice	
J. Debus, Heidelberg	R. Jeraj, Madison	S.N. Powell, New York	
T.F. Delaney, Boston	P.A.S. Johnstone, Bloomington	M. Pruschy, Zürich	
A. Del Guerra, Pisa	P. Keall, Stanford	L. Pyllkanen, Brussels	

ICTR-PHE 2012



SUPPORTING ENTITIES

In collaboration with The European School of Oncology



CERN
European Organization
for Nuclear Research



European Society for Therapeutic
Radiology and Oncology



European Society for Therapeutic Radiology and Oncology

Under the auspices of the
European Organisation for
Research and Treatment of Cancer



Fondazione FARO, Geneva



Fondazione TERA, Novara



University of Geneva,
and Geneva University Hospital



Association of Radiotherapy and Oncology
of the Mediterranean area



European Network for
Light Ion Hadron Therapy



European Novel Imaging Systems
for Ion therapy



Particle Training Network for European
Radiotherapy



Union of Light Ion Centres in Europe



Research Training in 3D Digital Imaging
for Cancer Radiation Therapy

ENTERVISION

With the
support of





ICTR-PHE 2012



Conference Arrangements and Organization

Venue

All sessions will be held at the Centre International de Conférences de Genève - International Conference Center of Geneva (CICG), conveniently located near the International Airport and major highways, the railway station, Lake Geneva and the historic old town. A vast choice of hotels offers the delegates first-rate hospitality just a stone's throw from the conference centre.

Conference Environment and Climate

Distinguished by its unique geographical position in the heart of Europe, state-of-the-art technology, and high-quality services, Geneva is the ideal venue for international events and a top conference centre where the cross-fertilization of ideas encourages an open mind and objective view of the world. Located between the Alps and the Jura mountains, at the extreme south-west of Switzerland and the Lake Léman, Geneva is the central cross-roads of Western Europe. Geneva is situated at a 373-meter altitude, which together with the lake, tempers the prevailing continental climate. In March temperatures usually range between 8 and 15°. Snow falls in the nearby Alps are frequent at this period of the year.

Registration

Information about the registration process is available on the website <http://cern.ch/ICTR-PHE12>

Registration Fee

Early registration	Swiss Francs	400	(deadline: October 3, 2011)
Late registration	Swiss Francs	700	(deadline: January 15, 2012)
On site registration	Swiss Francs	1'000	

The registration fee covers access to the Conference, a copy of the final programme and conference proceedings, coffee breaks and lunches during the Conference. Fees transferred later than February 1, 2012 may not be credited to the Conference account prior to the Congress registration. Therefore, it is mandatory to provide the registration desk personnel with a copy of the transfer order as proof of payment. Registration fees will be refunded, with a reduction of 80 CHF for administrative charges, only if notification of cancellation will have reached the Conference Secretariat before January 15, 2012. No refunds will be issued after this date and no-shows are not eligible for a refund. All refunds will be made within 3-4 weeks after the Conference. If you register but cannot attend the Conference, you may elect to pass on your registration to another person with your Organization.

Language

The language of the Conference will be English. No simultaneous translation is foreseen.

Conference Abstracts

The Conference abstracts will be published as a supplement to Radiotherapy and Oncology (Green Journal).

Accreditation, travel grants

A list of accreditations (European Accreditation Council for Continuing Medical Education (EACCME) and American Medical Association (AMA), as well as available travel grants will be regularly updated on the Conference website.



ICTR-PHE 2012



Projection facilities

Powerpoint and PDF files will be used.

Posters

All posters will be on continuous display throughout the Conference.

Technical Exhibition

An exhibition will take place in the Conference Center Main Hall, close to the lecture and poster presentation halls. The technical exhibition will remain open during the whole Conference period.



Swiss International Air Lines is proud to be the Official Carrier for the **ICTR-PHE 2012** and is offering special Congress Fares to all participants. These Congress Fares offer reductions of up to 25% depending on the fare type, route and space availability. Congress Fares are valid on the entire SWISS route network for flights to Switzerland, including flights operated by partner airlines under an LX flight number. These fares are now bookable for the travel period 14 days prior to and 14 days after the event.

To take advantage of this offer, book easily and conveniently through SWISS.COM via the following link: www.swiss.com/event

Please enter your email address and the following **event code: 4004-3632-4041-9268**. The special SWISS congress fare is marked with a "C". It may not necessarily be the lowest fare but it offers flexibility in the event of rebooking or cancellation. SWISS looks forward to pampering you on board with typical Swiss hospitality.

Conference Executive Office

Department of Radio-Oncology, Clinique de Genolier
4, route du Muids, CH-1272 Genolier
Switzerland

Phone + 41 22 366 99 59
Fax + 41 22 366 99 61
E-mail addresses info-ictr-phe-2012@cern.ch

During the Conference:

Centre International de Conférences Genève - International Conference Center of Geneva (CICG)
rue de Varembe 17, 1202 Geneva
Phone: + 41 22 791 91 11
Fax: + 41 22 791 90 64



ICTR-PHE 2012



Award Recipients

G.E. Adams Lecture

Award funded by the CR-UK/MRC Gray Institute for Radiation Oncology & Biology, Oxford University.

ICTR-PHE 2012 Recipient: I. Stratford, Manchester ICTR 2009

Previous G.E. Adams Lecturers:

- ICTR 2000: J.M. Brown, San Francisco
 - ICTR 2003: L.J. Peters, Melbourne
 - ICTR 2006: R.H. Withers, Los Angeles
 - ICTR 2009: A. Begg, Amsterdam
-

E. van der Schueren Award

Award funded by the European School of Oncology, Milano

ICTR-PHE 2012 Recipient: M.D. Anderson Cancer Center, Houston

Previous E. van der Schueren Recipients:

- ICTR 2000: Department of Experimental Clinical Oncology, University of Aarhus
 - ICTR 2003: Gray Laboratory, Northwood
 - ICTR 2006: Institut Gustave Roussy, Villejuif
 - ICTR 2009: Memorial Sloan Kettering Cancer Center, New-York
-

ESTRO Lecture

Lecture funded by the European Society for Therapeutic Radiology and Oncology

ICTR-PHE 2012 Recipient: P. Lambin, Maastricht

Previous ESTRO Lecturer:

- ICTR 2006: S.M. Bentzen, Madison
 - ICTR 2009: A. van der Kogel, Nijmegen
-

G.H. Fletcher Lecture

Lecture funded by the MD Anderson Cancer Center, Houston

ICTR-PHE 2012 Recipient: M. Baumann, Dresden

Previous G.H. Fletcher Lecturer:

- ICTR 2000: H. Bartelink, National Cancer Institute, Amsterdam
- ICTR 2006: L. Milas, M.D. Anderson Cancer, Houston
- ICTR 2009: A. Lee, Hong Kong



ICTR-PHE 2012



ICTR-PHE 2012: Abstract submission

All accepted abstracts will be published by Radiotherapy and Oncology ("Green Journal"). All abstracts will be submitted electronically. Electronic submission will begin on June 15, 2011 and will continue till October 3, 2011. Abstracts can be submitted directly through the conference website (<http://cern.ch/ICTR-PHE12/abstract.html>) or as an MSWORD 6.0 formatted file concomitantly sent to the following two e-mail addresses: jbernier@genolier.net and jacques.bernier@unige.ch

All abstracts will undergo review by international experts in the relevant scientific field.

The submitted abstracts will contain:

1. in CAPITAL LETTERS, the title of the abstract (max. 240 characters).
2. the names of authors (for instance: Dubois A, Jones NN) and institutions, noting the author reference number next to each institution name. Please underline the name of the presenting author. List each author's institution, city and state omitting department or division. Separate each institution name with a comma.
3. the text of your abstract (max. 600 words) in the following order: Purpose/Objective; Material and Methods; Results; Conclusions. Tables and/or figures may be included at the end of the abstract.
4. up to 3 key words should be listed in the abstract, using Medline or Index Medicus.

Important information:

1. Abstracts

- Please proof your abstract carefully: once an abstract has been selected, it may not be revised prior to publication.
- Abstracts are not eligible for review if they are incomplete or if they don't follow the guidelines.
- The Organizing Committee accepts no responsibility for missing the submission deadline.

2. Full-length articles

Full articles can be submitted to Radiotherapy and Oncology (Green Journal), mentioning they have been presented at ICTR-PHE 2012. These manuscripts will be directly mailed to the Journal Editorial Office (Editor-in-Chief: Prof. J. Overgaard) and will be reviewed according to the Radiotherapy and Oncology rules. As in the past, a number of contributions presented during the ICTR-PHE 2012 Conference will be selected by the Editor and their authors will be asked to prepare and submit a full-length article to Radiotherapy and Oncology.

Inquiries

Jacques Bernier MD, PD

Department of Radio-Oncology, Clinique de Genolier

4, route du Muids, CH-1272 Genolier Switzerland

Phone: + 41.22.366.9959

Fax: + 41.22.366.9961

E-mail addresses: info-ictr-phe-2012@cern.ch, jbernier@genolier.net or jacques.bernier@unige.ch



ICTR-PHE 2012



Scientific Programme

In the Arena

General Research Areas

Functional Imaging	Experimental Therapeutics
Developmental Radiation Physics	Early clinical testing
Molecular Pathology and Oncology	Radiobiology in therapy and space science
Structural Biology	Radioisotopes in diagnostics and therapy
Human Cancer Genetics	Prospects in medical imaging
Pre-Clinical Data	Novel technologies in radiation therapy

Specific Topics (non exhaustive list)

- Molecular imaging
- Positron emission tomography
- New markers in CT/PET
- Targeted imaging including hypoxia markers
- Brachytherapy
- Radio-surgery
- Navigation systems
- Single-Cell Microbeams
- Microbeam probes of cellular radiation response
- Magnetic field research
- Intensity modulated radiation therapy (IMRT)
- Tomotherapy
- Particle radiotherapy, hadrontherapy
- Image-guided radiotherapy, tissue motion
- Sparing normal tissues and critical organs
- Novel approaches in Quality Assurance
- Telematics
- Biologic and physical optimization in treatment planning
- Bio-mathematical approaches for experimental data
- Novel approaches in fractionation alteration
- Gene expression profiling
- Predictive assays
- Cell cycle and response to treatment
- Mechanisms of radiation induced cell death
- How to develop a successful cancer drug (chemo-radiation approaches)?
- Pitfalls in developing cancer treatment agents
- Applications of proteomics and genomics in drug discovery
- Mechanistic combinations
- Practical issues in tissue research
- Tumor vaccines
- AKT/PTEN/Survival pathways
- New targeting strategies: basic mechanisms and clinical outcome
- Drug radioresistance
- Molecular targeting
- Receptors
- Structure-activity relationships
- Tumor hypoxia
- Hypoxic cytotoxins
- Micro-environmental determinants of response to radiation
- Tumor vasculature
- Vascular disrupting agents
- Tumor endothelial cell interactions
- Angiogenesis and metastasis inhibitors
- Radiation effects on angiogenesis
- Apoptosis pathway targeting agents
- Proteasome inhibitors



ICTR-PHE 2012



Stress pathway inhibitors
Chromatin modifying agents
Cellular therapies and cytokines
Monoclonal antibodies and target toxins/nuclides
Radiosensitizers: in vitro and in vivo models
Radioprotectors
Genetic control of cancer cell and normal tissue Radiosensitivity
Intra- and inter-cellular signaling cascades induced by radiation
Signal transduction modulators
Cyclins and CDKs
Telomerase-targeting agents
Gene therapy and antisense approaches
Optimising targets for angiogenic inhibition
Stroma as a target
DNA, protein, and membrane chemistry
DNA damage recognition
DNA repair in tumor and normal tissues
DNA adducts
Normal tissue radiobiology
Antimetabolites
Bioreductive agents
Topoisomerase I / II inhibitors
Tubulin-interacting agents
DNA-interactive agents
Prodrugs
Drug delivery
Drug resistance and modifiers
Radiation interactive agents
Immunotherapy and ionizing radiation
Hormonal agents
Tumor tissue banks
Track structure applications
Oxidative stress
Bystander effects and radiotherapy
Microdosimetry
Genomic instability
Tumor susceptibility genes
Radiation carcinogenesis
Epigenetics
Genomics
Proteomics
Histones and response to radiation
Ubiquitin system in cancer therapy
Novel organisms for studying radiation response
Stem cells (tumor response and normal tissue damage)
Hyperthermia
Photodynamic Therapy
Radiobiology
Radiation oncology
Particle therapy
Radiation therapy
Treatment plans in radiotherapy
Radioisotopes
Nuclear medicine
Medical imaging
Challenges for simultaneous PET-MRI
Time of Flight PET
Treatment of moving targets
Scanned ion beam therapy
Linac
Cyclotron
Technology in emerging markets
Comprehensive engineering in radiotherapy



SCIENTIFIC PROGRAMME AT A GLANCE

Monday 27 February	Tuesday 28 February	Wednesday 29 February	Thursday 1 March	Friday 2 March
Opening Ceremony	ESTRO Lecture	G.H. Fletcher Lecture	Proffered papers <ul style="list-style-type: none"> • Biology, Physics, Clinics. 	
Radiobiology in therapy and space science <ul style="list-style-type: none"> • Missing data in radiation effects in deep space. • Missing data for Treatment Planning Systems in ion therapy. • Radiobiological research for improving particle therapy. • Treatment of radiation-resistant tumours. • Future needs. 	Prospects in detectors and medical imaging <ul style="list-style-type: none"> • Position-sensitive detectors. • Compton cameras. • New methods of photon detection. • Time-of-Flight for PET. • Challenges of hybrid PET/MRI. • Fast image reconstruction algorithms for in-situ treatment planning. 	Plenary lectures <ul style="list-style-type: none"> • Physics meet Biology. • Physics meet Clinics. • In-room Imaging. 	Forum <ul style="list-style-type: none"> • Tumor micro-environment. • Clinical radiation research. • Mitigation/repair of radiation damage: stem cells, modifiers, interventions. 	Symposium <ul style="list-style-type: none"> • Towards customized treatments: the head-and-neck example. • Molecular biology and predictive markers. • Hadrontherapy.
LUNCH	LUNCH	Plenary lectures <ul style="list-style-type: none"> • Radio-isotopes in therapy. • Biological adaptive radiotherapy. • Improving precision in imaging and treatment. 	Forum <ul style="list-style-type: none"> • EORTC session. • Oral Poster Presentation. • Oral Poster Presentation. 	Forum <ul style="list-style-type: none"> • Repair mechanisms. • Functional imaging. • Radiosensitivity modulation.
LUNCH	LUNCH	LUNCH	LUNCH	LUNCH
Radiotopes in diagnostics and therapy <ul style="list-style-type: none"> • $^{99}\text{Mo}/^{99\text{m}}\text{Tc}$ supply and $^{99\text{Mo}}$ production. • Therapy of metastases and systemic tumours with radioisotopes. • Clinical experience with commercial beta-radioisotopes coupled to antibodies. • Role of radiotracers in drug development. 	Novel Technologies and therapy <ul style="list-style-type: none"> • New accelerators for medical applications. • Gantries for ions. • Scanning beams and moving targets. • Future developments. 	Symposium <ul style="list-style-type: none"> • Tumor targeting and normal tissue protection. • Image-guided prescription and planning of RT. • Long-term perspectives in Hadrontherapy. 	G. Adams Lecture	Workshops <ul style="list-style-type: none"> • Tumor hypoxia and tumor metabolism. • Finding the target, restoring the vision. • Improving precision in treatment planning and delivery.
		Symposium <ul style="list-style-type: none"> • New algorithms in treatment planning and delivery. • Monte Carlo in treatment planning. • Status and perspectives in radiology. 	Workshops <ul style="list-style-type: none"> • Targeting signaling pathways. • Biological and physical optimization of treatment plans. • Normal tissues. 	Proffered papers <ul style="list-style-type: none"> • Biology, Physics, Clinics.
			Proffered papers <ul style="list-style-type: none"> • Biology, Physics, Clinics. 	ESO Plenary Session and E. van der Schueren Award



ICTR-PHE 2012



Hotel Accommodation Form

Please fill-in the Hotel Booking form and send it to:

World Avenues SA – 14, rue Ferrier – CH – 1202 Geneva

e-mail: sales@world-avenues.ch

Tel. +41 22 906 94 00 – Fax. + 41 22 906 94 10

Family Name _____

First Name _____

Title _____

Company _____

Address _____

E-mail _____

City _____

State/Province _____ E-mail _____

Zip/Postal Code _____ Telephone _____

Telefax _____

HOTELS

Hotel 5*	Single Room	CHF. 425.-
----------	-------------	------------

Hotel 4*	Single Room	CHF. 350.-
----------	-------------	------------

Hotel 3*	Single Room	CHF. 250.-
----------	-------------	------------

The rates are per room per night including tax, services and breakfast

Please book

Single room : _____ Hotel Category: _____

Double room: _____ Hotel Category: _____

Arrival _____ Departure _____ Number of nights _____



ICTR-PHE 2012



PAYMENT

Credit Card _____

Cardholder Name _____

Card Number _____

Expiry Date _____

Security Number _____

Billing Address if _____

American Express Card _____

Bank transfer to
Bank
Clearing
Swift
IBAN

World Avenues S.A.
Credit Suisse, CH-1211 Geneva 70
4835
CRESCHZZ12A
CH50 0483 5046 9213 6100 0

TERMS & CONDITIONS

- Rates are in Swiss Francs per room per night and include breakfast, services, taxes VAT and free public transportation for the duration of the stay (for participants with a hotel booking)
- 100% payment of total confirmed reservation at time of order
- Full prepayment for late arrivals and early departures
- Amendment and modification have to sent in writing only
- Bank charges are at the client's expenses
- Payment non refundable in case of cancellation received after January 16 2012